At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 111 enrolled
Drug / intervention
Doxercalciferol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in the Treatment of Subjects With Moderate to Severe Chronic Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating Doxercalciferol and Placebo for Moderate to Severe Chronic Plaque Psoriasis. Completed, enrolled 111 participants across 19 sites.
Detailed Summary
The purpose of this study was to evaluate the safety and effectiveness of an investigational drug called doxercalciferol in participants with moderate to severe chronic plaque psoriasis, in comparison with a placebo ("sugar pill"). All study related care was provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation was 28 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2008
Enrollment StartApr 2008
Primary CompletionFeb 2009
Study CompletionJun 2009
TodayJul 2026
First PostedJan 25, 2008
Enrollment StartApr 1, 2008
Primary CompletionFeb 1, 2009
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.4 years ago
Interventions
Doxercalciferoldrug
Placebodrug